AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT04398472 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: KIND Challenge
Description: The KIND challenge consists of nominating an activity to complete over a 4 week period. The activities involve doing an activity with others in your neighbourhood. These activities are positive, engaging and feasible to the average individual. Activities adhere to relevant country or state department health and safety guidelines. For example; having a chat with a neighbour online, or bringing in rubbish bins for an elderly neighbour.
Study NCT02898467 — intervention group
Intervention type: OTHER
Intervention: diabetics
Description: additional blood and urine collection during usual medical care endarterectomy samples during usual medical care
Study NCT02898467 — intervention group
Intervention type: OTHER
Intervention: non-diabetics
Description: additional blood and urine collection during usual medical care endarterectomy samples during usual medical care
Study NCT01626170 — intervention group
Intervention type: OTHER
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study NCT00747877 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cyclophosphamide
Description: Given orally
Study NCT00747877 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: melphalan
Description: Given IV
Study NCT00747877 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: autologous hematopoietic stem cell transplantation
Description: Patients undergo autologous hematopoietic stem cell transplantation on day 0.
Study NCT00916578 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation Therapy
Description: 50-57 Gy per faction once or twice a day, 5 days a week, for about 5 -7 weeks, about 15-30 minutes each time.
Study NCT00916578 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine
Description: During 5-7 weeks of radiation therapy, 825 mg/m2 (pills) by mouth, 2 times a day, about 12 hours apart, 30 minutes after eating food and about 2 hours before radiation therapy.
Study NCT03104023 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Staple line inversion
Description: A staple line inversion will be performed with a running suture of Polypropylene 2/0
Study NCT03104023 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Staple line buttressing
Description: The gastric section will be performed with a stapler with preloaded buttress material
Study NCT02886351 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nitrous Oxide
Description: Nitrous Oxide at 60%-70% concentration administrated by mask, to achieve cooperation in Pediatric dentisry
Study NCT00849056 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: albiglutide
Description: albiglutide weekly subcutaneous injection
Study NCT00849056 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: placebo weekly subcutaneous injection
Study NCT03808766 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: embolization
Description: Patient with a diagnosis of HCC and a treatment plan to receive partial hepatectomy will receive transarterial embolization under local anesthesia 2 weeks before the surgery. Angiographic examinations of the tumor before and after embolization of the tumor will be performed. Histological examination of the tumor in the surgical specimens will be performed.
Study NCT02807922 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Zopiclone
Study NCT02807922 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT02242617 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Positive Airway Pressure (PAP)
Description: Continuous or auto-adjusting positive airway pressure (i.e. CPAP, APAP, and described here as PAP): a device which consists of a face mask attached to a plastic tube and a machine that blows compressed air through a patient's airway during sleep to keep the airway open
Study NCT02242617 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Mandibular Advancement Splints (MAS)
Description: Mandibular advancement splints (MAS): dental splints used to keep the mandible in an advanced position opening the upper airway during sleep
Study NCT03736018 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: CTCA
Description: Computed Tomography Cardiac angiography (CTCA) performed prior to invasive coronary angiogram (ICA).
Study NCT02323009 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Esophageal Balloon
Description: Esophageal balloon was used to measure esophageal pressure (Paux) which was used as an estimate of pleural pressure. Transpulmonary pressure (Ptp) was calculated as the difference between airway pressure (Pao) and Paux. Applied PEEP was then adjusted to overcome negative Ptp which we maintained between 0 to 10 cm H20. All measurements were made at end-expiration.
Study NCT02323009 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Cstat
Description: PEEP was adjusted to achieve the best CStat in this group of patients
Study NCT02674503 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Walking
Description: MP patients will participate in a program of progressive walking and transfer training up to three times a day, seven days a week throughout the hospital stay. MP patients will begin with assisted sitting, then standing, progressing to weight shifting and stepping in place, and then to walking as tolerated. The level of mobility recommended to the MP patient by the Walker will be dependent on the individual patient and will incorporate the activities patients were deemed able to do independent of cueing or assistance during each walking session.
Study NCT02674503 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Friendly visit
Description: UC patients will receive three times a day friendly visits, seven days a week by members of the research team to control for the daily attention that MP patients receive.
Study NCT02019355 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 5-fluorouracil 5% cream
Study NCT02019355 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5-fluorouracil 5% cream
Study NCT02019355 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Calcipotriol 0.005% ointment
Study NCT02019355 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vaseline
Study NCT00903201 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SB656933
Description: 20 mg
Study NCT00903201 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SB656933
Description: 50mg
Study NCT00903201 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: placebo
Study NCT01212510 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Blood sampling
Description: blood rate of ACE, CA19-9, circulating tumor cell, circulating tumor DNA
Study NCT04571489 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gimatecan
Description: Patients will receive gimatecan orally at 0.8mg/m2 on day 1-5 every 4 weeks.
Study NCT04571489 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: tegafur, gimeracil and oteracil potassium
Description: Patients will receive tegafur, gimeracil and oteracil potassium orally at 40 or 60mg twice daily on days 1 to 14 every 3 weeks.
Study NCT04571489 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: gemcitabine
Description: Patients will receive gemcitabine IV at 1000mg/m2 on days 1、8 every 3 weeks.
Study NCT04370496 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Minimally invasive surgery using endoscopic stapler
Description: Radical hysterectomy by minimally invasive surgery (laparoscopic or robotic) will be done with the help of an endoscopic stapler in cutting and suturing the uterine cervix.
Study NCT02664688 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Lumbar stabilization exercises
Description: The home-exercise program included an initial phase, with use of therapeutic heat via a hot pack for 15 minutes at the lumbosacral region, stretching exercises of the thoracolumbar fascia, hip flexors, hamstrings plus the stabilization exercises to encourage stabilizing motor patterns and determine the neutral position of the spine, with the target in control of transversus and internal oblique abdominis, multifidus, pelvic floor muscles, and diaphragmatic breathing control. Progression stages included hot packs, stretching exercises, and lateral, anterior bridges, leg raises in supine position, and arm and leg lifts in quadruped position (bird-dog)
Study NCT02664688 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Flexor exercises
Description: The home-exercise program included a hot pack for 15 minutes and flexor exercises routine
Study NCT01933724 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5 mg prednisone
Description: Subjects will be randomized to take 5 mg per day of prednisone for a 6 month period.
Study NCT01933724 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 0 mg prednisone
Description: Subjects will be randomized to taper their prednisone dose to no prednisone for a 6 month period.
Study NCT01446705 — intervention group
Intervention type: OTHER
Intervention: Active Health Information Exchange
Description: Patients selected to share data between the VA \& external healthcare agencies.
Study NCT01446705 — intervention group
Intervention type: OTHER
Intervention: Non-Active Health Information exchange
Description: Patients not selecting to share data
Study NCT02934178 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Shigella sonnei Strain WRSS1 Vaccine
Description: Live attenuated, oral Shigella WRSS1 vaccine
Study NCT02934178 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Sterile saline solution
Study NCT03813108 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CPS-immunization
Description: Subjects will be immunized 3 times by exposure to the bites of P. falciparum NF135.C10 infected mosquitoes while taking mefloquine prophylaxis.
Study NCT03813108 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: malaria challenge infection, P. falciparum NF135.C10
Description: Subjects will receive bites from 5 Anopheles mosquitoes infected with Plasmodium falciparum NF135.C10 sporozoites.
Study NCT03813108 — intervention group
Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: malaria challenge infection, P. falciparum NF135.C10
Description: Subjects will receive bites from 5 Anopheles mosquitoes infected with Plasmodium falciparum NF135.C10 sporozoites.
Study NCT03813108 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: malaria challenge infection, P. falciparum NF54
Description: Subjects will receive bites from 5 Anopheles mosquitoes infected with Plasmodium falciparum NF54 sporozoites.
Study NCT03813108 — intervention group
Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: malaria challenge infection, P. falciparum NF54
Description: Subjects will receive bites from 5 Anopheles mosquitoes infected with Plasmodium falciparum NF54 sporozoites.
Study NCT03813108 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CPS-immunization (A/L)
Description: Subjects will be immunized 3 times by exposure to the bites of P. falciparum NF135.C10 infected mosquitoes and receive presumptive treatment with artemether/lumefantrine initiated on day 7 after each immunization.
Study NCT03813108 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atovaquone / Proguanil Oral Tablet [Malarone]
Description: All participants will be treated with atovaquone/proguanil (1000/400 mg (= 4 tablets) 1×/day during 3 consecutive days) when they develop a malaria infection or on day 28 after malaria challenge infection.
Study NCT03813108 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Atovaquone / Proguanil Oral Tablet [Malarone]
Description: All participants will be treated with atovaquone/proguanil (1000/400 mg (= 4 tablets) 1×/day during 3 consecutive days) when they develop a malaria infection or on day 28 after malaria challenge infection.
Study NCT00557466 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: indacaterol
Description: Indacaterol delivered by multiple dose dry powder inhaler (TWISTHALER® device).
Study NCT00557466 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: formoterol
Description: Formoterol delivered by oral inhalation via AEROLIZER® inhalation device.
Study NCT00557466 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: placebo to indacaterol
Description: Placebo TWISTHALER® device
Study NCT00557466 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo to indacaterol
Description: Placebo TWISTHALER® device
Study NCT00557466 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: placebo to formoterol
Description: Placebo AEROLIZER® device
Study NCT00557466 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo to formoterol
Description: Placebo AEROLIZER® device
Study NCT00557466 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: short acting β2- agonist
Description: 100 μg / 90 μg salbutamol/albuterol Metered Dose Inhaler (MDI) or equivalent dose of Dry Powder Inhaler (DPI).
Study NCT00557466 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: short acting β2- agonist
Description: 100 μg / 90 μg salbutamol/albuterol Metered Dose Inhaler (MDI) or equivalent dose of Dry Powder Inhaler (DPI).
Study NCT00557466 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: short acting β2- agonist
Description: 100 μg / 90 μg salbutamol/albuterol Metered Dose Inhaler (MDI) or equivalent dose of Dry Powder Inhaler (DPI).
Study NCT02349438 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: senofilcon A
Description: A soft spherical contact lens
Study NCT02349438 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: senofilcon A
Description: A soft spherical contact lens
Study NCT02349438 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: lotrafilcon B
Study NCT02349438 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: lotrafilcon B
Study NCT01949545 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carfilzomib
Description: Carfilzomib was administered by IV injection over 30 minutes
Study NCT00532623 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gemcitabine plus Vinorelbine
Description: Gemcitabine, 1,000mg/m2 and Vinorelbine, 25mg/m2, on day 1 and day 8, every 3 week cycles
Study NCT00532623 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sequential
Description: Gemcitabine monotherapy followed by Vinorelbine monotherapy:~-Gemcitabine: 1,200 mg/m2, intravenously, on day 1 and day 8 in 3 week cycles. Vinorelbine: 30 mg/ m2, intravenously, on day 1 and day 8 in 3 week cycles.
Study NCT04198168 — intervention group
Intervention type: DRUG
Intervention: IV crystalloid fluid bolus
Description: The participant receives IV fluid as a standardised bolus of 7 ml/kg (ideal body weight).
Study NCT00408499 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cetuximab
Description: Cetuximab will be administered intravenously weekly at the maximum tolerated dose (determined in Phase I portion of the study) on a 28 day cycle. Participants will be in this study for at least 2 cycles (8 weeks). If the evaluations show that this treatment has been effective against the participant's cancer, he/she will continue the therapy.
Study NCT00408499 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: erlotinib
Description: Erlotinib will be taken by mouth daily on a 28 day cycle. It is in tablet form. The dose will be determined in Phase I portion of the study. Participants will be in this study for at least 2 cycles (8 weeks). If the evaluations show that this treatment has been effective against the participant's cancer, he/she will continue the therapy.
Study NCT03957993 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Occupational Therapy via Telehealth
Description: The caregiver will be with the participant in their home environment receiving occupational therapy via Telehealth (video-calling) with the occupational therapist.
Study NCT03957993 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard of Care Occupational Therapy
Description: The caregiver and participant will be in the clinic receiving occupational therapy in-person with the occupational therapist.
Study NCT00668616 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cyclophosphamide, Epirubicin, Paclitaxel
Description: 4 cycles of 600 mg/m² cyclophosphamide i.v. and 90 mg/m2 Farmorubicin i.v. on day 1, q21d followed by 4 cycles of 175 mg/m² Taxol, day 1, q21d
Study NCT00668616 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Epirubicin, Paclitaxel, Filgrastim
Description: cycle 1-4: 120 mg/m² Epirubicin i.v. on day 1, q14d, 5 µg/kg s.c. filgrastim day 5-10 (if leucocytes are lower than 10000/µl) cycle 5-8: 175 mg/m² Paclitaxel i.v. on day 1, q14d, 5 µg/kg s.c. filgrastim day 5-10 (if leucocytes are lower than 10000/µl)
Study NCT04113603 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Urinary malignancy
Description: Single bolus three phase CTU
Study NCT04168957 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oraxol
Description: Oraxol (oral paclitaxel + oral HM30181AK-US)~Paclitaxel: supplied as capsules HM30181 methanesulfonate monohydrate: supplied as HM30181AK-US tablets
Study NCT03355144 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Daily Supplementation with Coffee
Description: At the beginning of study week 2 (study day 8), two coffee machines (one Nespresso Inissia and one Hamilton Beach 46205 12 Cup Programmable Coffee Maker) will be installed in the resident work rooms at each site.~Subjects will be provided with free coffee beans, milk, cream, sugar and sweetener
Study NCT04546763 — intervention group
Intervention type: DEVICE
Intervention: Study Watch
Description: The Study Watch is a miniaturized wearable device made with biocompatible contact materials containing various sensors capable of measuring physiological and environmental metrics.
Study NCT04546763 — intervention group
Intervention type: DEVICE
Intervention: Zio XT
Description: The Zio XT Patch, the reference device, is a FDA-cleared single-patient use, continuously recording ECG monitor that can be worn up to 14 days.
Study NCT02549118 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tenoxicam
Study NCT02549118 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pethidine
Study NCT01408472 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NT-501 CNTF Implant
Description: Single implantation of CNTF-secreting NT-501 device into one eye
Study NCT01898416 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5-AMINOLEVULINIC ACID (5-ALA), is a non fluorescent prodrug.
Description: 60 mg/kg 5-ALA prepared solution given orally, 3-5 hours before induction of anesthesia.~Red light laser given by a Dye laser system, wave length of 635nm, in s dose of 150J/cm for 2000 seconds (33 minutes) will be given to tumor bed. In case of positive margins a second operation and 5-ALA administration or irradiation will be given.
Study NCT01648764 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY2334737
Description: Administered orally
Study NCT01262586 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vildagliptin
Study NCT01262586 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Glimepiride
Study NCT04542941 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: COVID Convalescent Plasma
Description: Plasma collected from recovered COVID 19 individuals
Study NCT04023968 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: YESplus workshop
Description: See description in Arms section.
Study NCT04023968 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: WOW! workshop
Description: See description in Arms section.
Study NCT03031925 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: ANXA2
Description: serum and urinary concentration
Study NCT03031925 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: ANXA2
Description: serum and urinary concentration
Study NCT02950389 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PMMA filter
Study NCT02950389 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: HFR17 filter
Study NCT02950389 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: F7 filter
Study NCT02305316 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIA 9-1067 non-micronized
Study NCT02305316 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIA 9-1067 micronized
Study NCT00903968 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Plerixafor
Study NCT00903968 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bortezomib
Study NCT00903968 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Study NCT03176914 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: prevention and management of childhood illnesses at community level
Description: provision of critical health education and targeted promotion services to the participants in their locality
Study NCT03176914 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: conventional community interventions
Description: community health programs as the sole source of health education
Study NCT00843349 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lanthanum Carbonate
Description: Phosphorus binder